Squamous cell carcinoma, also known as squamous cell skin cancer, is a common type of skin cancer. Alfa Cytology is a world leader in the research of skin cancer. With our extensive experience and advanced platform, we can provide the best solutions for squamous cell carcinoma.
Introduction to Squamous Cell Carcinoma
Skin squamous cell carcinoma (SCC) is the second most common skin cancer, characterized by abnormal and accelerated growth of squamous cells. This type of cancer is usually not life-threatening and most grow slowly. But if left untreated, it may spread deep and damage nerves, blood vessels, and any other part of their pathway. In addition, in immunosuppressed conditions, even if the tumor is relatively small, squamous cell carcinoma that occurs is often more invasive than squamous cell carcinoma that occurs in non-immunosuppressed patients.
Fig.1 Multimodal of composition and spatial architecture in human SCC. (Ji, A. L., et al., 2020)
Targets of Squamous Cell Carcinoma Therapy Development
Classic platinum-based therapies were a common practice, before the emergence of receptor tyrosine kinase inhibitors (RTKIs). In addition, epidermal growth factor receptor (EGFR) blockers provide a legitimate, biologically based option. The following are the target genes that are repeatedly altered in SCC and their functions.
| Gene |
Function |
| TP53 |
Tumor suppressor |
| NOTCH1 |
Regulation of multiple differentiation processes |
| NOTCH2 |
Regulation of multiple differentiation processes |
| CDKN2A |
G1/S checkpoint |
| HRAS |
GTPase |
| NF1 |
RasGAP |
| PTEN |
Tumor suppressor |
Targets of Squamous Cell Carcinoma Therapy Development
Although most SCC cases are generally not fatal and can be controlled through surgical resection or radiation therapy, there is currently no systemic therapy approved for life-threatening late-stage diseases that cannot be removed. Below are some specific development pipelines related to potential therapies for SCC.
| Targets |
Therapeutics |
Company |
Molecule Type |
Phase |
| LAG-3 |
Favezelimab + pembrolizumab (MK-4280a) |
Merck |
Monoclonal antibody |
|
| PD-1 |
MK-3475 |
Merck |
Monoclonal antibody |
|
| PD-1 |
Cemiplimab |
Regeneron |
Monoclonal antibody |
|
Our Services
Most SCC can be cured if detected and treated early. However, advanced squamous cell carcinoma of the skin is relatively more difficult to treat and may become dangerous, spreading to local lymph nodes, distant tissues, and organs. Therefore, Alfa Cytology is working on providing one-stop solutions for SCC, including but not limited to the following.
Therapeutic Development Platform
Cancer Modelling Platform
Preclinical Research Services
Models of Squamous Cell Carcinoma
Models of SCC are used to study the biology of the disease, its progression, treatment response, and the development of new therapies. Alfa Cytology offers a range of transgenic model options, each with specific advantages and limitations. In addition, we also provide a variety of related cell line culture and Xenograft animal model development services.
| Transgenic Models |
- p53 null mice model
- Epidermal growth factor receptor transgenic mice model
|
- Overexpressing STAT3 mice model
- Src family tyrosine kinases transgenic mice model
|
Alfa Cytology is committed to researching and studying skin cancer and provides one-stop services. Our cancer experts have many years of experience in the development of the latest therapies for SCC. Our preclinical services encompass a wide range of capabilities, including high-throughput screening, pharmacokinetic and pharmacodynamic evaluations, and advanced animal models. If you are interested in our service, please contact us for more information.
Reference
- Ji, A. L., et al.; (2020). Multimodal analysis of composition and spatial architecture in human squamous cell carcinoma. Cell, 182(2), 497-514.
! For research use only.
Related Services
